Cariprazine (Vraylar)

What it treats

Cariprazine is approved by the U.S. Food and Drug Administration to treat schizophrenia in adults, to treat the manic, mixed, and depressive episodes of bipolar I disorder, and to be used as an add-on to an antidepressant for major depressive disorder. That range of uses across the mood-and-psychosis spectrum is unusually broad for a single medication.

When cariprazine is prescribed for depression, that does not mean the diagnosis has changed to psychosis. It is added at a low dose alongside an antidepressant that has helped only partway. Used this way, it is a booster, not a replacement.

How it works

Cariprazine is an atypical antipsychotic, but it works differently from most of them. Nerve cells in the brain pass messages using chemical messengers, and dopamine is one of them. Most antipsychotics simply block dopamine activity. Cariprazine is a dopamine partial agonist, which means it dampens dopamine activity when levels are high and can modestly support it when levels are low.

What makes cariprazine unusual is its preference for a specific dopamine receptor called D3, which sits in brain circuits linked to motivation, reward, and cognition. That receptor profile is part of why it has been useful across schizophrenia, mania, and bipolar depression. How that translates into day-to-day benefit is not fully understood, and it is worth being honest about that.

Receptor mechanism (detail)

Cariprazine is a D3-preferring D3/D2 partial agonist with about ten-times higher affinity for the D3 receptor than the D2 receptor. The D3 receptor is concentrated in reward and cognition circuits, and that selectivity is what most distinguishes cariprazine from other dopamine partial agonists. It is also a 5-HT1A partial agonist and a 5-HT2B antagonist, both of which likely contribute to its antidepressant and negative-symptom effects. Cariprazine has two long-lived active metabolites with half-lives measured in one to three weeks, which means the medication continues to work well after a dose change and that changes in effect take a few weeks to become visible.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual. Cariprazine is dosed in a fairly narrow milligram range across all its uses.

For schizophrenia, doses generally run 1.5 to 6 mg once daily. For bipolar mania or mixed episodes, 3 to 6 mg once daily is typical. For bipolar depression, 1.5 to 3 mg once daily is typical. For depression add-on, 1.5 to 3 mg once daily is typical. Cariprazine is taken once a day with or without food, and the prescriber sets and adjusts the dose based on response, side effects, and other medications.

Safety monitoring

• Akathisia and other movement effects. Restlessness is the most common dose-related side effect of cariprazine, and it should be asked about at every early visit. It is treatable. An involuntary-movement screen (AIMS) every six months looks for tardive dyskinesia over the long term.
• Metabolic labs. Weight and BMI at baseline, weeks 4, 8, and 12, then quarterly. Fasting glucose or HbA1c and a lipid panel at baseline, three months, and at minimum annually. Cariprazine's metabolic risk is lower than olanzapine or clozapine, but it is not zero.
• Blood pressure at baseline and periodically.
• Long half-life. Because cariprazine and its active metabolites stay in the body for weeks, effect changes lag behind dose changes. Neither benefits nor side effects arrive on the day of a change.
• Prolactin usually stays normal or low; check only if symptoms suggest it.

Metformin co-commencement. Aoife Carolan / Schizophrenia Bulletin guideline.

A clinical guideline led by Aoife Carolan strongly recommends co-commencing metformin alongside high-risk antipsychotics like olanzapine or clozapine. This proactive approach helps mitigate severe metabolic side effects, significantly reducing antipsychotic-induced weight gain and improving insulin resistance. The Schizophrenia Bulletin guideline states that when prescribing olanzapine or clozapine, metformin should be initiated immediately to prevent weight gain and cardiometabolic issues. Cariprazine is lower metabolic risk under the guideline; metformin is recommended if weight rises by more than 3 percent of pre-medication weight or if other cardiometabolic conditions are present.

Typical titration used in the guideline: 500 mg once daily → 500 mg twice daily after one week → 500 mg increments every two weeks as tolerated → up to 1000 mg twice daily by about week six. Contraindicated with eGFR below 30 mL/min/1.73 m²; renal function is checked annually and metformin is held during acute illness or dehydration.

Source: Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.

What to expect

Common side effects

Most people get some side effects. The common ones include:

• Restlessness or an inability to sit still. This is called akathisia, and it is the most common dose-related side effect of cariprazine.
• Other movement effects, called extrapyramidal symptoms, such as stiffness or tremor.
• Trouble sleeping.
• Nausea, especially in the first weeks.
• Headache.

Akathisia is worth flagging early, because it is treatable. A prescriber may lower the dose, slow the pace of increases, or add a medication to settle it. If a side effect is severe, or it is not improving, that is a conversation to have with the prescriber rather than a reason to stop on your own.

Serious side effects and warnings

Serious problems are uncommon, but a few are worth knowing.

Boxed warning. Like all antipsychotics, cariprazine carries an FDA boxed warning that it increases the risk of death in older adults with dementia-related psychosis, and antipsychotics are not approved for that use. When cariprazine is used as an add-on for depression, the antidepressant boxed warning also applies: antidepressants can increase suicidal thoughts and behaviors in children, teenagers, and young adults under 25, especially early in treatment or after a dose change. Any worsening of mood, agitation, or new thoughts of self-harm should prompt contact with the prescriber promptly.

• Metabolic effects. Cariprazine can cause weight gain and rises in blood sugar and cholesterol. These tend to be smaller than with olanzapine or quetiapine, but they are still monitored over time.
• Tardive dyskinesia. A movement disorder linked to long-term antipsychotic use, involving repetitive involuntary movements, often of the face or mouth. Risk rises with longer use.
• Neuroleptic malignant syndrome. A rare but serious reaction. Signs include high fever, muscle stiffness, confusion, and an unstable heartbeat or blood pressure. It is a medical emergency.
• Delayed side effects. Because cariprazine has such a long half-life, a side effect that appears weeks after a dose change may still be related to that change.

This is not medical advice. Any concern about a serious side effect should be discussed with a prescriber promptly.

Sexual side effects

Cariprazine has a relatively low rate of sexual side effects compared with some older antipsychotics. It can still affect sex drive or function for some people. If that happens, it is worth raising with a prescriber rather than living with it, because there are usually options.

Weight, appetite, and sleep

Weight gain is possible with cariprazine, but it tends to be smaller than with olanzapine, quetiapine, and several other antipsychotics. Weight, blood sugar, and cholesterol are checked periodically, since effects vary from person to person.

Cariprazine can be activating for some people, and trouble sleeping is one of its more common early side effects. If sleep problems persist, that is worth raising with the prescriber.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber. Ranges are typical framework only, not a prescription for any individual.

Cariprazine comes as oral capsules. It is taken once a day with or without food. The prescriber chooses a starting dose and adjusts it gradually, keeping in mind that changes take longer to show than with most antipsychotics because of the long half-life.

Missed doses and interactions

If you miss a dose, the general guidance is to take it when you remember, unless it is almost time for the next dose. In that case, skip the missed dose and carry on. Don't take two doses to make up for one. Because the medication stays in the body for weeks, a single missed day is less disruptive than with shorter-acting medications.

Cariprazine is processed by liver enzymes that other medications can speed up or slow down. Strong inhibitors and strong inducers of one enzyme in particular (CYP3A4) require a dose change or a switch. Because of that, the prescriber and pharmacist need a full list of your medications and supplements, including over-the-counter ones. Alcohol is not formally prohibited, but it can worsen side effects and is generally best limited.

Stopping and tapering

Stopping cariprazine should be gradual and planned with a prescriber. The body adjusts to the medication over time, and stopping suddenly can cause discomfort or a return of the symptoms it was treating. Because the medication has such a long half-life, its levels naturally taper over weeks even after the last dose, and a prescriber will factor that into any stopping plan.

Pregnancy and breastfeeding

This is an area where individual circumstances matter and the decision belongs with a clinician. Untreated schizophrenia, bipolar disorder, and depression carry their own risks during pregnancy, and cariprazine also passes into breast milk. Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber so the specific risks and benefits can be weighed for their situation. This is not medical advice.

Cost and generic availability

Cariprazine is available under the brand name Vraylar. A generic version has become available in some markets but is not yet universal. Because of that, cariprazine is often more expensive than older antipsychotics such as aripiprazole or haloperidol. Insurance coverage and manufacturer copay programs vary, the pharmacist and prescriber can help identify options.

Common questions

What is a D3-preferring partial agonist? Dopamine acts on several receptor subtypes. Cariprazine prefers the D3 receptor, which sits in brain circuits linked to motivation, reward, and cognition. In practical terms it means cariprazine engages those circuits somewhat differently from other dopamine partial agonists, and it is one reason cariprazine is used across schizophrenia, mania, and bipolar depression.

Why does it take so long to work? Cariprazine and its active metabolites stay in the body for one to three weeks. Because of that long half-life, both benefits and side effects can lag a dose change by several weeks. Patience across the first month or two is often needed.

What is akathisia? Akathisia is a feeling of restlessness and an inability to sit still, often with an urge to keep moving. It is the most common dose-related side effect of cariprazine. It is treatable, so it is worth reporting to the prescriber early.

Will it make me gain weight? Weight gain is possible, but it tends to be smaller than with olanzapine or quetiapine. Weight, blood sugar, and cholesterol are monitored over time.

Questions to ask your prescriber

• What are we hoping this treats, and how will we know it's working?
• Which side effects should I expect early, and which ones should I call about?
• How long should I wait before deciding whether it is helping?
• What should I watch for in terms of restlessness or movement changes?
• If we decide to stop it later, how would we do that safely?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Prescribing information (DailyMed).
• MedlinePlus, U.S. National Library of Medicine.
• National Institute of Mental Health.
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 3rd edition.
• National Institute for Health and Care Excellence (NICE). CG178, Psychosis and schizophrenia in adults.
• American Diabetes Association / American Psychiatric Association. Consensus Statement on Antipsychotic Drugs and Obesity and Diabetes.
• Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.